Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MGLL | Q99685 | 2/20 | 0.38 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.36 |
| ▸ | PKM | P14618 | 1/20 | 0.36 |
| ▸ | CRBN | Q96SW2 | 3/20 | 0.34 |
| ▸ | MLYCD | O95822 | 1/20 | 0.34 |
| ▸ | HDAC4 | P56524 | 3/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.33 |
| ▸ | FASN | P49327 | 2/20 | 0.33 |
| ▸ | CECR2 | Q9BXF3 | 1/20 | 0.32 |
| ▸ | NAMPT | P43490 | 1/20 | 0.32 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
| ▸ | SLC6A7 | Q99884 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20708737 | 0.90 | SLC6A7 (0.36) | MGLLMEN1KMT2AFASNHPGD | |
| SCHEMBL20695169 | 0.85 | MEN1 (0.47) | MGLLMEN1KMT2AHPGDSLC6A7 | |
| SCHEMBL20695388 | 0.82 | HRH3 (0.46) | MGLLCRBNSLC6A7 | |
| SCHEMBL20695191 | 0.82 | RXRA (0.46) | MGLLMEN1KMT2AHPGDSLC6A7 | |
| SCHEMBL20695210 | 0.82 | MAPK1 (0.50) | CRBNMEN1LMNAKMT2ADDB1 | |
| SCHEMBL20695153 | 0.81 | SLC6A7 (0.42) | MGLLHPGDSLC6A7 | |
| SCHEMBL20695446 | 0.80 | HPGD (0.47) | MGLLPKMCRBNMEN1KMT2A | |
| SCHEMBL20695136 | 0.79 | KIF11 (0.48) | MGLL | |
| SCHEMBL20695167 | 0.79 | MGLL (0.39) | MGLLPKMCRBNFASNNAMPT | |
| SCHEMBL20695461 | 0.78 | TTR (0.44) | MGLLPKMCRBNDDB1NAMPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10610520-B2 | Heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2020-04-07 | — | — | US | disclosed |
| US-20190125728-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2019-05-02 | — | — | US | disclosed |
| US-20190125728-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2019-05-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190125728-A1 | HETEROCYCLIC COMPOUND | MAG, HTT, ACHE | MGLL 138/4885KDM4C 2626/4885PKM 2129/4885 |
| US-10610520-B2 | Heterocyclic compound | MAG, HTT, ACHE | MGLL 138/4885KDM4C 2626/4885PKM 2129/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.